These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 27993665)

  • 1. Active Surveillance for Favorable Risk Prostate Cancer in African Caribbean Men: Results of a Prospective Study.
    Meunier ME; Eyraud R; Sénéchal C; Gourtaud G; Roux V; Lanchon C; Brureau L; Blanchet P
    J Urol; 2017 May; 197(5):1229-1236. PubMed ID: 27993665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active surveillance in prostate cancer is possible for Afro-Caribbean population: Comparison of oncological outcomes with a Caucasian cohort.
    Percot M; Robert G; Bladou F; Ferrière JM; Bensadoun H; Bernhard JC; Alezra E; Capon G; Sénéchal C; Gourtaud G; Brureau L; Roux V; Blanchet P; Eyraud R
    Prog Urol; 2020 Sep; 30(10):532-540. PubMed ID: 32593527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer.
    Adamy A; Yee DS; Matsushita K; Maschino A; Cronin A; Vickers A; Guillonneau B; Scardino PT; Eastham JA
    J Urol; 2011 Feb; 185(2):477-82. PubMed ID: 21167529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metastatic Prostate Cancer in Men Initially Treated with Active Surveillance.
    Yamamoto T; Musunuru HB; Vesprini D; Zhang L; Ghanem G; Loblaw A; Klotz L
    J Urol; 2016 May; 195(5):1409-1414. PubMed ID: 26707510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Biopsy Compliance on Outcomes for Patients on Active Surveillance for Prostate Cancer.
    Detsky JS; Ghiam AF; Mamedov A; Commisso K; Commisso A; Zhang L; Liu S; Klotz L; Loblaw A; Vesprini D
    J Urol; 2020 Nov; 204(5):934-940. PubMed ID: 32330406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population-based study of grade progression in patients who harboured Gleason 3 + 3.
    Sampurno F; Earnest A; Millar J; Frydenberg M; Murphy D; Delprado W; Evans S
    World J Urol; 2017 Nov; 35(11):1689-1699. PubMed ID: 28500489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active Surveillance for Intermediate Risk Prostate Cancer: Survival Outcomes in the Sunnybrook Experience.
    Musunuru HB; Yamamoto T; Klotz L; Ghanem G; Mamedov A; Sethukavalan P; Jethava V; Jain S; Zhang L; Vesprini D; Loblaw A
    J Urol; 2016 Dec; 196(6):1651-1658. PubMed ID: 27569437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer.
    Maggi M; Cowan JE; Fasulo V; Washington SL; Lonergan PE; Sciarra A; Nguyen HG; Carroll PR
    J Urol; 2020 Dec; 204(6):1222-1228. PubMed ID: 33157570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer.
    Klotz L; Vesprini D; Sethukavalan P; Jethava V; Zhang L; Jain S; Yamamoto T; Mamedov A; Loblaw A
    J Clin Oncol; 2015 Jan; 33(3):272-7. PubMed ID: 25512465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.
    Iremashvili V; Manoharan M; Rosenberg DL; Soloway MS
    BJU Int; 2013 Apr; 111(4):574-9. PubMed ID: 22564446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Clinical Significance of Multiple Negative Surveillance Prostate Biopsies for Men on Active Surveillance-Does Cancer Vanish or Simply Hide?
    Chu CE; Cowan JE; Fasulo V; Washington SL; de la Calle C; Shoemaker J; Carroll PR
    J Urol; 2021 Jan; 205(1):109-114. PubMed ID: 33198555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate Cancer.
    Newcomb LF; Schenk JM; Zheng Y; Liu M; Zhu K; Brooks JD; Carroll PR; Dash A; de la Calle CM; Ellis WJ; Filson CP; Gleave ME; Liss MA; Martin F; McKenney JK; Morgan TM; Tretiakova MS; Wagner AA; Nelson PS; Lin DW
    JAMA; 2024 Jun; 331(24):2084-2093. PubMed ID: 38814624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. National Comprehensive Cancer Network® Favorable Intermediate Risk Prostate Cancer-Is Active Surveillance Appropriate?
    Aghazadeh MA; Frankel J; Belanger M; McLaughlin T; Tortora J; Staff I; Wagner JR
    J Urol; 2018 May; 199(5):1196-1201. PubMed ID: 29288120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guy's and St Thomas NHS Foundation active surveillance prostate cancer cohort: a characterisation of a prostate cancer active surveillance database.
    Shah S; Beckmann K; Van Hemelrijck M; Challacombe B; Popert R; Dasgupta P; Rusere J; Zisengwe G; Elhage O; Santaolalla A
    BMC Cancer; 2021 May; 21(1):573. PubMed ID: 34011308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance.
    Perlis N; Sayyid R; Evans A; Van Der Kwast T; Toi A; Finelli A; Kulkarni G; Hamilton R; Zlotta AR; Trachtenberg J; Ghai S; Fleshner NE
    J Urol; 2017 Jan; 197(1):75-83. PubMed ID: 27457260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3 + 4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance.
    Gearman DJ; Morlacco A; Cheville JC; Rangel LJ; Karnes RJ
    J Urol; 2018 May; 199(5):1188-1195. PubMed ID: 29225057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of Metastasis in Men with Grade Group 2 Prostate Cancer Managed with Active Surveillance at a Tertiary Cancer Center.
    Carlsson S; Benfante N; Alvim R; Sjoberg DD; Vickers A; Reuter VE; Fine SW; Vargas HA; Wiseman M; Mamoor M; Ehdaie B; Laudone V; Scardino P; Eastham J; Touijer K
    J Urol; 2020 Jun; 203(6):1117-1121. PubMed ID: 31909690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study.
    Kearns JT; Faino AV; Newcomb LF; Brooks JD; Carroll PR; Dash A; Ellis WJ; Fabrizio M; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Zheng Y; Lin DW
    Eur Urol; 2018 May; 73(5):706-712. PubMed ID: 29433973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial.
    Godtman RA; Holmberg E; Khatami A; Stranne J; Hugosson J
    Eur Urol; 2013 Jan; 63(1):101-7. PubMed ID: 22980443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active surveillance: the Canadian experience with an "inclusive approach".
    Klotz L
    J Natl Cancer Inst Monogr; 2012 Dec; 2012(45):234-41. PubMed ID: 23271779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.